Atara biotherapeutics announces submission of investigational new drug application for ata3219 for treatment of lupus nephritis

Thousand oaks, calif.--(business wire)---- $atra #cart--atara biotherapeutics, inc. (nasdaq: atra), a leader in t-cell immunotherapy, leveraging its novel allogeneic epstein-barr virus (ebv) t-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced its recent submission of an investigational new drug (ind) application to the u.s. food and drug administration (fda) for the use of ata3219 as a monotherapy for the treatment of systemic lupus erythematosu.
ATRA Ratings Summary
ATRA Quant Ranking